Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1996 Dec;89(4):483–487. doi: 10.1046/j.1365-2567.1996.d01-790.x

The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide.

C D Partidos 1, M Pizza 1, R Rappuoli 1, M W Steward 1
PMCID: PMC1456583  PMID: 9014810

Abstract

The intranasal route has been shown to be effective for immunization. However, immunization via this route may require the use of potent and safe adjuvant. The construction of non-toxic mutants of heat labile enterotoxin of Escherichia coli (LT), which is a potent mucosal adjuvant, is a major breakthrough for the development of mucosal vaccines. In this study we have assessed the ability of an LT mutant (LTK63) to act as an adjuvant following intranasal co-immunization with a peptide corresponding to a measles virus cytotoxic T lymphocyte (CTL) epitope. LTK63 was more effective at potentiating the in vivo induction of peptide-specific and measles virus-specific CTL responses than was administration of the peptide in saline. A concentration of 10 micrograms/dose of LTK63 was found to be the most effective in potentiating the in vivo priming of peptide-specific and measles virus-specific CTL responses. These findings highlight the potential of the non-toxic mutant of LT as a safe mucosal adjuvant for use in humans.

Full text

PDF
483

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beauverger P., Chadwick J., Buckland R., Wild T. F. Serotype-specific and canine distemper virus cross-reactive H-2Kk-restricted cytotoxic T lymphocyte epitopes in the measles virus nucleoprotein. Virology. 1994 Aug 15;203(1):172–177. doi: 10.1006/viro.1994.1470. [DOI] [PubMed] [Google Scholar]
  2. Bowen J. C., Nair S. K., Reddy R., Rouse B. T. Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens. Immunology. 1994 Mar;81(3):338–342. [PMC free article] [PubMed] [Google Scholar]
  3. Bromander A., Holmgren J., Lycke N. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J Immunol. 1991 May 1;146(9):2908–2914. [PubMed] [Google Scholar]
  4. Carbone F. R., Bevan M. J. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med. 1990 Feb 1;171(2):377–387. doi: 10.1084/jem.171.2.377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Clarke C. J., Wilson A. D., Williams N. A., Stokes C. R. Mucosal priming of T-lymphocyte responses to fed protein antigens using cholera toxin as an adjuvant. Immunology. 1991 Mar;72(3):323–328. [PMC free article] [PubMed] [Google Scholar]
  6. Dale J. B., Chiang E. C. Intranasal immunization with recombinant group A streptococcal M protein fragment fused to the B subunit of Escherichia coli labile toxin protects mice against systemic challenge infections. J Infect Dis. 1995 Apr;171(4):1038–1041. doi: 10.1093/infdis/171.4.1038. [DOI] [PubMed] [Google Scholar]
  7. Di Tommaso A., Saletti G., Pizza M., Rappuoli R., Dougan G., Abrignani S., Douce G., De Magistris M. T. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect Immun. 1996 Mar;64(3):974–979. doi: 10.1128/iai.64.3.974-979.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Douce G., Turcotte C., Cropley I., Roberts M., Pizza M., Domenghini M., Rappuoli R., Dougan G. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1644–1648. doi: 10.1073/pnas.92.5.1644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gizurarson S., Tamura S., Aizawa C., Kurata T. Stimulation of the transepithelial flux of influenza HA vaccine by cholera toxin B subunit. Vaccine. 1992;10(2):101–106. doi: 10.1016/0264-410x(92)90025-f. [DOI] [PubMed] [Google Scholar]
  10. Gopas J., Itzhaky D., Segev Y., Salzberg S., Trink B., Isakov N., Rager-Zisman B. Persistent measles virus infection enhances major histocompatibility complex class I expression and immunogenicity of murine neuroblastoma cells. Cancer Immunol Immunother. 1992;34(5):313–320. doi: 10.1007/BF01741552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hathaway L. J., Partidos C. D., Vohra P., Steward M. W. Induction of systemic immune responses to measles virus synthetic peptides administered intranasally. Vaccine. 1995 Nov;13(16):1495–1500. doi: 10.1016/0264-410x(95)00111-d. [DOI] [PubMed] [Google Scholar]
  12. Lycke N., Strober W. Cholera toxin promotes B cell isotype differentiation. J Immunol. 1989 Jun 1;142(11):3781–3787. [PubMed] [Google Scholar]
  13. Lycke N., Tsuji T., Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol. 1992 Sep;22(9):2277–2281. doi: 10.1002/eji.1830220915. [DOI] [PubMed] [Google Scholar]
  14. Nashar T. O., Amin T., Marcello A., Hirst T. R. Current progress in the development of the B subunits of cholera toxin and Escherichia coli heat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes. Vaccine. 1993;11(2):235–240. doi: 10.1016/0264-410x(93)90023-q. [DOI] [PubMed] [Google Scholar]
  15. Partidos C. D., Vohra P., Steward M. W. Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides. Immunology. 1996 Feb;87(2):179–185. doi: 10.1046/j.1365-2567.1996.462527.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Partidos C. D., Vohra P., Steward M. W. Priming of measles virus-specific CTL responses after immunization with a CTL epitope linked to a fusogenic peptide. Virology. 1996 Jan 1;215(1):107–110. doi: 10.1006/viro.1996.0012. [DOI] [PubMed] [Google Scholar]
  17. Pizza M., Fontana M. R., Giuliani M. M., Domenighini M., Magagnoli C., Giannelli V., Nucci D., Hol W., Manetti R., Rappuoli R. A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit. J Exp Med. 1994 Dec 1;180(6):2147–2153. doi: 10.1084/jem.180.6.2147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Rager-Zisman B., Egan J. E., Kress Y., Bloom B. R. Isolation of cold-sensitive mutants of measles virus from persistently infected murine neuroblastoma cells. J Virol. 1984 Sep;51(3):845–855. doi: 10.1128/jvi.51.3.845-855.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Reddy R., Zhou F., Nair S., Huang L., Rouse B. T. In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. J Immunol. 1992 Mar 1;148(5):1585–1589. [PubMed] [Google Scholar]
  20. Spangler B. D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol Rev. 1992 Dec;56(4):622–647. doi: 10.1128/mr.56.4.622-647.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Tamura S. I., Asanuma H., Ito Y., Hirabayashi Y., Suzuki Y., Nagamine T., Aizawa C., Kurata T., Oya A. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur J Immunol. 1992 Feb;22(2):477–481. doi: 10.1002/eji.1830220228. [DOI] [PubMed] [Google Scholar]
  22. Tamura S., Yamanaka A., Shimohara M., Tomita T., Komase K., Tsuda Y., Suzuki Y., Nagamine T., Kawahara K., Danbara H. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine. 1994 Apr;12(5):419–426. doi: 10.1016/0264-410x(94)90118-x. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES